Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FTO degradation targeting enhances anti-tumor immunity

ABSTRACT: FTO degradation targeting enhances anti-tumor immunity

PROVIDER: PRJNA1053378 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27227219_1.fastq.gz	Fastqsanger.gz
	SRR27227219_2.fastq.gz	Fastqsanger.gz
	SRR27227220_1.fastq.gz	Fastqsanger.gz
	SRR27227220_2.fastq.gz	Fastqsanger.gz
	SRR27227221_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

FTO degradation targeting enhances anti-tumor immunity

Project description:The m6A RNA demethylase Fat mass and obesity-associated protein (FTO) is aberrantly upregulated in numerous cancers and promotes tumor development and therapeutic resistance. Here, using public datasets and screening, we show that FTO is ubiquitinated at lysine 162 by its E3 ligase DTX2, followed by recognition by UFD1, leading to degradation in the proteasomes. Furthermore, we identified vitamin E succinate (VES) as a natural first-in-class degrader for FTO by binding to FTO and DTX2, thus enhancing FTO-DTX2 interaction, leading to increased FTO ubiquitination and degradation and enhanced anti-tumor immunity and response to immunotherapy. Genetic or pharmacological FTO knockdown by VES increased m6A methylation in the LIF gene and thus decreased LIF mRNA decay, and thus sensitized tumor cells to T cell-mediated cytotoxicity. Taken together, our findings elucidated the underlying molecular mechanism for FTO protein degradation and the first natural FTO degrader that reprograms the anti-tumor immunity.

2024-11-25 | GSE250332 | GEO

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

Project description:BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

| PRJNA765317 | ENA

Targeting cathepsin B by cycloastragenol enhances anti-tumor immunity via inhibiting MHC-1 degradation and promoting the presentation of tumor antigen

Project description:Targeting cathepsin B by cycloastragenol enhances anti-tumor immunity via inhibiting MHC-1 degradation and promoting the presentation of tumor antigen

| PRJNA809393 | ENA

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

Project description:Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.

| PRJNA683080 | ENA

Targeting cathepsin B by cycloastragenol enhances anti-tumor immunity via inhibiting MHC-1 degradation and promoting the presentation of tumor antigen [RNA-seq]

Project description:Purpose:We want to elaborate the specific mechanism of CAG inhibiting the growth of transplanted mouse colon cancer cell MC38. Methods:After MC38 cells were inoculated into C57BL/6 mice for 6 days, the mice were evenly divided into PBS group and CAG group, and PBS and CAG (50mg / kg) were administered by gavage every day. On the 18th day, the mouse tumors were removed, and one tumor was selected to prepare single cell suspension for 10x-scRNA-seq and 10x-scATAC-seq. Results:We found that CAG promoted the antigen-presenting function of tumor cells and enhanced the killing ability of CD8 T cells. Conclusions:CAG enhances the antitumor immunity of CD8 T cells by promoting the antigen presentation of tumor cells.

2023-02-22 | GSE197228 | GEO

Targeting cathepsin B by cycloastragenol enhances anti-tumor immunity via inhibiting MHC-1 degradation and promoting the presentation of tumor antigen [ATAC-seq]

2023-02-22 | GSE197227 | GEO

FTO suppresses DNA repair by inhibiting PARP1

Project description:Maintaining genomic integrity and faithful transmission of genetic information are essential for the survival and proliferation of cells and organisms. DNA damage, which threatens the integrity of the genome, is rapidly sensed and repaired by mechanisms collectively known as DNA damage response in cells. Using an unbiased quantitative proteomic approach, we revealed the interactome of an RNA demethylase FTO (fat mass and obesity-associated protein). We identified a direct interaction with the DNA damage sensor protein PARP1 (poly-ADP-ribose polymerase 1), which dissociates upon ultraviolet (UV) stimulation. FTO inhibits PARP1 catalytic activity and controls its clustering in the nucleolus. Loss of FTO enhances PARP1 enzymatic activity and the rate of PARP1 recruitment to DNA damage sites, thus accelerating DNA repair and, consequently, cell survival. Thus, our study establishes FTO as an endogenous negative regulator of PARP1 and the UV-induced DNA damage response, which has implications for the treatment options of various cancers.

2025-03-26 | PXD041638 | Pride

FTO degrader inhibits acute myeloid leukemia by impairing ribosome biogenesis and translation

Project description:The fat mass and obesity-associated protein (FTO), an RNA m6A eraser, has been identified as a critical oncogenic factor in acute myeloid leukemia (AML). We presented the development of an FTO degrader(FP54) that selectively degrades FTO in AML cells, demonstrating superior efficacy both in vitro and in vivo. Mechanistically, FTO degradation increases m6A modifications on ribosome biogenesis related mRNAs and thus promotes YTHDF2-mediated degradation. This process impairs ribosome biogenesis and translation process, ultimately inhibiting AML progression.

2025-07-08 | GSE282823 | GEO

CTLA-4 tail fusion enhances CAR-T anti-tumor immunity

Project description:CTLA-4 tail fusion enhances CAR-T anti-tumor immunity

| PRJNA980728 | ENA

Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer

Project description:Epigenetic priming enhances anti-tumor immunity in resistant ovarian cancer

| PRJNA778066 | ENA